Pieter L Lindenbergh
Overview
Explore the profile of Pieter L Lindenbergh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
128
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lindenbergh P, van der Stegen S
Transfus Med Hemother
. 2025 Feb;
52(1):27-41.
PMID: 39944411
Background: The clinical success of autologous adoptive cell therapy (ACT) is substantial but wide application is challenged by the quality and quantity of the patient's immune cells and the need...
2.
Dobrin A, Lindenbergh P, Shi Y, Perica K, Xie H, Jain N, et al.
Nat Cancer
. 2024 Mar;
5(5):760-773.
PMID: 38503896
Chimeric antigen receptor T cells have dramatically improved the treatment of hematologic malignancies. T cell antigen receptor (TCR)-based cell therapies are yet to achieve comparable outcomes. Importantly, chimeric antigen receptors...
3.
van der Stegen S, Lindenbergh P, Petrovic R, Xie H, Diop M, Alexeeva V, et al.
Nat Biomed Eng
. 2024 Feb;
8(11):1500.
PMID: 38347164
No abstract available.
4.
van der Stegen S, Lindenbergh P, Petrovic R, Xie H, Diop M, Alexeeva V, et al.
Nat Biomed Eng
. 2022 Aug;
6(11):1284-1297.
PMID: 35941192
The production of autologous T cells expressing a chimaeric antigen receptor (CAR) is time-consuming, costly and occasionally unsuccessful. T-cell-derived induced pluripotent stem cells (TiPS) are a promising source for the...
5.
Mansilla-Soto J, Eyquem J, Haubner S, Hamieh M, Feucht J, Paillon N, et al.
Nat Med
. 2022 Jan;
28(2):345-352.
PMID: 35027758
Chimeric antigen receptors (CARs) are receptors for antigen that direct potent immune responses. Tumor escape associated with low target antigen expression is emerging as one potential limitation of their efficacy....
6.
Lu H, Molony R, Chen D, Jang S, Wolf B, Ewert S, et al.
Mol Cancer Ther
. 2020 Aug;
19(10):2089-2104.
PMID: 32847974
The sole inhibitory Fcγ receptor CD32b (FcγRIIb) is expressed throughout B and plasma cell development and on their malignant counterparts. CD32b expression on malignant B cells is known to provide...
7.
Frerichs K, Nagy N, Lindenbergh P, Bosman P, Marin Soto J, Broekmans M, et al.
Expert Rev Clin Immunol
. 2018 Feb;
14(3):197-206.
PMID: 29465271
Multiple myeloma (MM) is generally an incurable hematological malignancy with heterogeneous overall survival rates ranging from a few months to more than 10 years. Survival is especially poor for patients...